- call +1-201-465-4211
- email sales@mrinsights.biz
Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.
Scope of the Report:
The global Benign Prostatic Hyperplasia market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostatic Hyperplasia.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Benign Prostatic Hyperplasia market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostatic Hyperplasia market by product type and applications/end industries.
Market Segment by Companies, this report covers
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Drug Therapy
Dialysis
Other
Market Segment by Applications, can be divided into
Hospitals
Clinics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Benign Prostatic Hyperplasia Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia
1.2 Classification of Benign Prostatic Hyperplasia by Types
1.2.1 Global Benign Prostatic Hyperplasia Revenue Comparison by Types (2017-2023)
1.2.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Types in 2017
1.2.3 Drug Therapy
1.2.4 Dialysis
1.2.5 Other
1.3 Global Benign Prostatic Hyperplasia Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Benign Prostatic Hyperplasia Market by Regions
1.4.1 Global Benign Prostatic Hyperplasia Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia Status and Prospect (2013-2023)
1.5 Global Market Size of Benign Prostatic Hyperplasia (2013-2023)
2 Manufacturers Profiles
2.1 Abbott
2.1.1 Business Overview
2.1.2 Benign Prostatic Hyperplasia Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbott Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.2 Allergan
2.2.1 Business Overview
2.2.2 Benign Prostatic Hyperplasia Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Allergan Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.3 Astellas Pharma
2.3.1 Business Overview
2.3.2 Benign Prostatic Hyperplasia Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.4 Boehringer Ingelheim Pharma
2.4.1 Business Overview
2.4.2 Benign Prostatic Hyperplasia Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.5 Eli Lilly and Company
2.5.1 Business Overview
2.5.2 Benign Prostatic Hyperplasia Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline
2.6.1 Business Overview
2.6.2 Benign Prostatic Hyperplasia Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck
2.7.1 Business Overview
2.7.2 Benign Prostatic Hyperplasia Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.8 Pfizer
2.8.1 Business Overview
2.8.2 Benign Prostatic Hyperplasia Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Pfizer Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sanofi
2.9.1 Business Overview
2.9.2 Benign Prostatic Hyperplasia Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sanofi Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2016-2017)
3 Global Benign Prostatic Hyperplasia Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostatic Hyperplasia Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Players Market Share
3.3 Market Competition Trend
4 Global Benign Prostatic Hyperplasia Market Size by Regions
4.1 Global Benign Prostatic Hyperplasia Revenue and Market Share by Regions
4.2 North America Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
5 North America Benign Prostatic Hyperplasia Revenue by Countries
5.1 North America Benign Prostatic Hyperplasia Revenue by Countries (2013-2018)
5.2 USA Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
5.3 Canada Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
5.4 Mexico Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
6 Europe Benign Prostatic Hyperplasia Revenue by Countries
6.1 Europe Benign Prostatic Hyperplasia Revenue by Countries (2013-2018)
6.2 Germany Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
6.3 UK Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
6.4 France Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
6.5 Russia Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
6.6 Italy Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Benign Prostatic Hyperplasia Revenue by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia Revenue by Countries (2013-2018)
7.2 China Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
7.3 Japan Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
7.4 Korea Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
7.5 India Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
8 South America Benign Prostatic Hyperplasia Revenue by Countries
8.1 South America Benign Prostatic Hyperplasia Revenue by Countries (2013-2018)
8.2 Brazil Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
8.3 Argentina Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
8.4 Colombia Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Benign Prostatic Hyperplasia by Countries
9.1 Middle East and Africa Benign Prostatic Hyperplasia Revenue by Countries (2013-2018)
9.2 Saudi Arabia Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
9.3 UAE Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
9.4 Egypt Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
9.5 Nigeria Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
9.6 South Africa Benign Prostatic Hyperplasia Revenue and Growth Rate (2013-2018)
10 Global Benign Prostatic Hyperplasia Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia Revenue and Market Share by Type (2013-2018)
10.2 Global Benign Prostatic Hyperplasia Market Forecast by Type (2018-2023)
10.3 Drug Therapy Revenue Growth Rate (2013-2023)
10.4 Dialysis Revenue Growth Rate (2013-2023)
10.5 Other Revenue Growth Rate (2013-2023)
11 Global Benign Prostatic Hyperplasia Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia Revenue Market Share by Application (2013-2018)
11.2 Benign Prostatic Hyperplasia Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
12 Global Benign Prostatic Hyperplasia Market Size Forecast (2018-2023)
12.1 Global Benign Prostatic Hyperplasia Market Size Forecast (2018-2023)
12.2 Global Benign Prostatic Hyperplasia Market Forecast by Regions (2018-2023)
12.3 North America Benign Prostatic Hyperplasia Revenue Market Forecast (2018-2023)
12.4 Europe Benign Prostatic Hyperplasia Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Benign Prostatic Hyperplasia Revenue Market Forecast (2018-2023)
12.6 South America Benign Prostatic Hyperplasia Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Benign Prostatic Hyperplasia Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Benign Prostatic Hyperplasia Picture
Table Product Specifications of Benign Prostatic Hyperplasia
Table Global Benign Prostatic Hyperplasia and Revenue (Million USD)
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
